JBUON 2014; 19(2): 342-349 ISSN: 1107-0625, online ISSN: 2241-6293 • www.jbuon.com E-mail:
[email protected]
REVIEW ARTICLE
Mantle cell lymphoma-current literature overview Ivica Pejcic1,2, Ivan Petkovic1, Svetislav Vrbic1,2, Sladjana Filipovic1,2, Mirjana Balic1, Ana Cvetanovic1 1University Oncology Clinic, Clinical Centre Nis; 2University of Nis, Medical Faculty, Oncology Department, Nis, Serbia
Summary Mantle cell lymphoma (MCL) is a distinct subtype of lymphoma identified as a particular entity in the early 1990s. The prognosis of MCL is generally poor, and is considered one of the worst among all B-cell lymphomas. In general, conventional chemotherapy is only palliative and the median duration of remissions is only 1-2 years. With the exception of allogeneic hematopoietic stem cell transplantation (allo-SCT), current treatment approaches are not curative and the corresponding survival curve is characterized by a relatively steep and continuous decline, with a median survival of about 4 years and
